Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DigitalOcean Holdings Inc (DOCN) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance

DigitalOcean Holdings IncTrade
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)Trade

Price performance (Past 24H)

Key statistics

DigitalOcean Holdings Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? DigitalOcean Holdings Inc trades at $125.66 (market cap $14.97B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 3.9× DigitalOcean Holdings Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.36% dividend while DigitalOcean Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DigitalOcean Holdings Inc for 43 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.

DOCNTAK
Market Cap
$14.97B$58.16B
Volume
1,385,1942,467,530
Sector
TechnologyHealth
52-Week High
$181.29$19.05
52-Week Low
$37.30$13.23
Typical Hold Time
43 Days0 Days
Enterprise Value
$15.73B$86.04B
Dividend Yield
—3.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DigitalOcean Holdings Inc

DigitalOcean trades at $123.90, down 5.47% today, but maintains strong fundamental momentum with 29% revenue growth in Q2 2026 and consistent earnings beats. The company shows robust profitability with 57.2% gross margins and 23.3% net income margins, though valuation multiples remain elevated with a P/E of 57.9. Recent product launches including Agent Droplets and a $725 million equipment financing facility support continued AI-driven growth. Technical indicators show mixed signals with bullish oscillators but bearish moving averages, creating a consolidation pattern near key support at $122.

DigitalOcean presents a compelling growth story with strong AI adoption tailwinds, trading 28% below analyst consensus target of $172.73. The primary investment thesis hinges on continued execution of AI-native cloud strategy, though risks include high valuation multiples, negative shareholder equity, and competitive pressure from larger cloud providers. Institutional ownership trends remain positive with recent acquisitions by Bank of America and California State Teachers Retirement System.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DOCN
100% Buy0% Sell
Avg holding period · 43 Days
TAK
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About DigitalOcean Holdings Inc

DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.

Read more on DOCN →

About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.

Read more on TAK →